An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Brief Summary

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

Intervention / Treatment

  • Drug: Psilocybin

Condition or Disease

  • Treatment Resistant Depression

Phase

Study Design

Study type: Interventional
Status: Recruiting
Study results: No Results Available
Age: 18 Years to 65 Years   (Adult, Older Adult)
Enrollment: 15 ()
Funded by: Other|Industry

Masking

Clinical Trial Dates

Start date: Mar 01, 2021
Primary Completion: Apr 01, 2022
Completion Date: Apr 01, 2022
Study First Posted: Jun 16, 2020
Results First Posted: Aug 30, 2020
Last Updated: Dec 21, 2021

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 65

This clinical trial is recruiting

Are you interested in participating in this trial or others? We'd love to help.

More Details

NCT Number: NCT04433858
Other IDs: 14947563
Study URL: https://ClinicalTrials.gov/show/NCT04433858
Last updated: Jun 16, 2022